2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada
; 5(4):214-222, 2022.
Article
in English
| EuropePMC | ID: covidwho-2102334
ABSTRACT
We provide an update to the Association of Medical Microbiology and Infectious Disease Canada foundation guidance for the upcoming 2020–2021 influenza season in Canada. Important issues for this year include the implications of co-circulation of SARS-CoV-2, the role of diagnostic testing, and a restatement of dosing and administration recommendations for neuraminidase inhibitors in various age groups and underlying health conditions. Although peramivir and baloxivir are now licensed in Canada, neither is currently marketed, so this guidance focuses on further optimizing the use of oseltamivir and zanamivir.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Language:
English
Journal:
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS